PCV chemotherapy

Phase 3Small molecule

HHospices Civils de Lyon

PCV chemotherapy is one of 7 small molecule programs targeting Oligodendroglioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligodendrogliomaRecruiting

OligodendrogliomaPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Oligodendroglioma

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

L19TNF

1 3

PCV chemotherapy

HHospices Civils de Lyon

Phase 3

1 4

Tislelizumab Plus Bevacizumab

HHenan Provincial People's Hospital

Phase 2

1 5

Fluzone

Voranigo

Matulane

LLeadiant Biosciences, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Oligodendroglioma

NCT04702581

Clinical

Trials by Indication[1]

Oligodendroglioma1 trial

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

Recruiting·HHospices Civils de Lyon·Phase 3·NCT04702581·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PCV chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCV chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCV chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHospices Civils de Lyon

PCV chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Oligodendroglioma1 trial

References

Drug Info

Quick Facts

Related News